196 An enhanced recovery after surgery pathway for cesarean delivery decreases hospital stay and cost Emily E. Fay, Laurent Bollag, Carlos Delgado, Leah M. Savitsky, Elizabeth Mills, JoAnn L. Slater, Jane Hitti University of Washington, Seattle, WA OBJECTIVE: Enhanced recovery after surgery (ERAS) programs provide a multidisciplinary, evidence-based approach to the care of surgical patients. They have been shown to decrease postoperative length of stay and cost in several surgical specialties but have not been well studied in obstetric patients undergoing cesarean delivery (CD). We hypothesized that implementation of an ERAS CD pathway would decrease postoperative length of stay and direct cost compared to historical controls. STUDY DESIGN: We conducted a retrospective cohort study comparing postoperative length of stay and direct cost among women on the ERAS CD pathway in the first year of implementation (4/1/2017-3/ 31/2018, n¼531) compared to historical controls (3/1/2016-2/28/ 2017, n¼661). Women with pregestational diabetes on insulin prior to pregnancy, preeclampsia with severe features, and those with complex pain needs were excluded from baseline and implementation groups. ERAS CD pathway participation was determined by order set usage. Analysis was stratified for women undergoing planned (no labor, n¼530) and unplanned (labor, n¼662) CD. Demographic and clinical characteristics, postoperative length of stay and direct cost for the baseline and implementation groups were compared using c 2 and t-tests. RESULTS: During the first year of implementation, 531 (83%) of 640 eligible women were included in the ERAS CD pathway. Body mass index was marginally higher in the baseline group for unplanned CD (32.57 vs. 31.47, p¼0.049). There were no other significant differences in demographic or clinical characteristics between baseline and implementation groups. Compared to baseline, implementation of the ERAS CD pathway resulted in a significant decrease in postoperative length of stay by 7.8% or 4.86 hours overall (p<0.001) and for both planned and unplanned CD (Table 1) . Total postoperative cost decreased by 8.4% or $642.85 per patient overall (p<0.001) and for both planned and unplanned CD (Table 1) . There were no significant differences in readmission rates. CONCLUSION: Implementation of an ERAS program for women having planned or unplanned CD was associated with significantly decreased postoperative length of stay and significant cost-savings per patient, without increase in hospital readmissions.
197 The additional benefit of a repeat corticosteroid therapy for neonates born < 34 week' gestation [2011] [2012] [2013] [2014] [2015] [2016] . The respiratory (RDS, TTN, Bronchopulmonary dysplasia, meconium aspiration syndrome) and CNS (Encephalopathy, IVH grade III-IV, seizures, PVL) and longterm morbidity (retinopathy of prematurity and necrotizing enterocolitis) were compared between neonates who were treated with only a single course of CS (CS-group) to those treated with r-CS (at least 14 days following the first CS administration e r-CS group). RESULTS: 1) Of 67,007 neonates (66,553 deliveries) born during the study period, 660 (1%) met inclusion criteria. Of them, 87 (13.2%) neonates were treated with r-CS.
2) The mean gestational age at delivery and birthweight were comparable between the groups (31.6AE1.8 vs. 31.7AE2.0 weeks, p¼0.839, and 1,607AE429 vs. 1,675AE473g, p¼0.206, respectively). The median (IQR) of the timeinterval from CS and r-CS administration to delivery was 4.9 (1-19.5) and 4 (1-17) days, respectively.
3) The r-CS group had significantly lower rates of RDS (23.0 vs. 34.8%, p¼0.037), respiratory morbidity (27.6 vs. 40.5%, p¼0.025) and total morbidity (31.0 vs. 44.7%, p¼0.020). No differences were found in terms of small for gestational age rate (16.1 vs. 12.0%, p¼0.298) or in CNS morbidity. 4) Furthermore, we assessed the complications rates according to gestational age at delivery. Neonatal morbidity was inversely correlated with gestational age at delivery, with an additional reduction for neonates treated with r-CS (Figure) . In multivariable analysis, after controlling for maternal age, HTN disorders, multiple gestations, gestational age at delivery, mode of delivery, meconium-stained amniotic fluid. birthweight centile and neonatal gender, neonatal morbidity rate was significantly lower in r-CS group (Table) . CONCLUSION: A repeat course of antenatal corticosteroids can reduce the risk for RDS and respiratory morbidity as compared to neonates treated with only a single course born in the same gestational week. No adverse effect on the neonate birthweight was shown. Therefore, a single repeat course of antenatal corticosteroids should be considered in women who are less than 34 weeks' gestation who are at risk for preterm delivery.
